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The acquisition of drug-resistance mutations among African
children living with in human immunodeﬁciency virus on an-
tiretroviral treatment has been scarcely reported. This threatens
the overall success of antiretroviral programs and the clinical
outcomes of children in care. We present a well characterized
series of children from rural Tanzania with acquired drug-
resistance mutations to contribute to the better understanding
of this emerging public health concern.
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There are few data on the acquisition of drug-resistance muta-
tions among African children living with human immunodeﬁ-
ciency virus (HIV) on antiretroviral treatment (ART). Overall,
in resource-limited settings, HIV-1 treatment failure in children
is estimated to be 40% [1]. Virologic suppression and long-term
treatment success are harder to achieve in children than in
adults [2]. This is mostly due to high pre-ART viral loads
(VLs), poorer virologic response, and risk of subtherapeutic
drug concentrations caused by limited pediatric drug formula-
tions, variable pharmacokinetics, and rapid changes in body
weight [1, 3–7]. These factors, often associated with suboptimal
adherence, may promote the emergence of drug-resistance
mutations. Only 1 study from Kenya has described the pattern
of acquired drug-resistance mutations in African children pre-
senting ART failure [5, 8]. In Tanzania, a small study found a
virologic failure (VF) rate of 58%, 100% with drug-resistance
mutations [9].
The emergence of acquired drug-resistance mutations in chil-
dren threatens ART programs in sub-Saharan Africa and needs
to be studied further. We present a well characterized series of
children from a rural Tanzanian setting with treatment failure
due to the acquisition of drug-resistance mutations.
MATERIAL AND METHODS
Study Setting and Population
The children in this study attended the Chronic Diseases Clinic
of Ifakara (CDCI), in the Saint Francis Referral Hospital. The
CDCI works in cooperation with the Ifakara Health Institute,
the Swiss Tropical and Public Health Institute, and the Univer-
sity Hospitals of Basel and Bern. Patients attending the CDCI
are offered informed consent to be enrolled in the Kilombero
and Ulanga Antiretroviral Cohort (KIULARCO) [10]. The
KIULARCO study received ethical clearance from the corre-
sponding ethical review boards in Tanzania and Switzerland.
This is the largest peripheral HIV cohort in Tanzania with al-
most 8000 patients. In January 2013, a pediatric and prevention
of mother-to-child transmission (PMTCT) unit, named “The
One Stop Clinic of Ifakara”, was established within the CDCI.
By March 2015, 340 children and adolescents were under active
follow-up. Care and treatment for patients were provided ac-
cording to the National AIDS Control Program. CD4 counts
were used to routinely monitor the ART response. Viral load
was requested by clinicians after treatment failure was suspected
due to poor immunological or clinical evolution. In case VL was
detected, HIV drug-resistance genotyping was performed.
Clinical Data
At each visit, clinical, laboratory, and pharmacy data were
collected electronically. Adherence was estimated using self-
reported adherence and pill counting and considered “sub-
optimal” if <95% of the prescribed pills had been taken. The
individual prescriptions were reviewed to assess their adequacy.
For children transferred from other facilities, ART dosage was
checked by direct observation of their drugs at the enrollment
visit.
Viral Load and Genotypic Resistance Testing
Blood samples were collected in 8 mL BD Vacutainer EDTA
collection tubes. Plasma HIV RNAVL and HIV drug-resistance
genotypes were determined at the Ifakara Health Institute lab-
oratory. Cell-free plasma was collected by centrifugation at 956
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relative centrifugal force for 5 minutes and frozen at −80°C
until testing for VL or drug-resistance genotyping. Human im-
munodeﬁciency virus RNA from plasma was extracted using
the QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germa-
ny), following the manufacturer’s protocol. Viral RNA quanti-
ﬁcation was performed with the TaqMan RNA-to-CT 1-Step
Kit (Life Technologies) using the StepOne Real-Time PCR sys-
tem (Life Technologies), with a detection limit of 200 viral RNA
copies/mL. Human immunodeﬁciency virus drug-resistance
genotyping was performed by Sanger sequencing on an ABI
Genetic Analyzer (4-capillary model 3130) using a validated
in-house polymerase chain reaction protocol [11]. Human im-
munodeﬁciency virus-1 drug resistance was predicted according
to the Stanford University’s HIV Drug Resistance Database Pro-
gram version 6.2.0 (http://hivdb.stanford.edu).
RESULTS
We present a series of children with acquired drug-resistance
mutations: 10 of 12 enrolled in the CDCI at HIV diagnosis
and 2 of 12 (#11, #12) transferred to our clinic after ART initi-
ation. Six patients (#1–#6) were identiﬁed through a previous
cross-sectional analysis within KIULARCO. The remaining 6
children were identiﬁed prospectively after presenting unsatis-
factory evolution: patients #7, #8, and #9 presented poor CD4
increase, although they did not meet the World Health Organi-
zation (WHO) criteria of immunological failure; patient #10
presented clinical failure; patient #11 had been exposed to low
doses of antiretrovirals; and patient #12 presented with both
immunological and clinical failure.
Clinical Characteristics
The clinical characteristics of the patients are summarized in
Table 1. Median age at ART initiation was 6.4 years (interquar-
tile range [IQR], 5.3–9.4). Ten children were orphans. None was
diagnosed through a PMTCT program or had documented ex-
posure to PMTCT. Remarkably, 10 of 12 children were born be-
fore 2006, the year in which the ﬁrst PMTCT intervention was
scaled-up to our district. All children were initiated on a non-
nucleoside reverse-transcriptase inhibitor (NNRTI)-based regi-
men. During follow-up, 7 of 12 had been exposed to more than
1 ﬁrst-line regimen, mostly due to unavailability of drugs. In 3
of 7 cases, children were switched back and forth more than
once. Only 1 child (#12) was treated for tuberculosis before pre-
senting treatment failure. Median time on ART at the time
when VF was detected was 3.7 years (IQR, 3.2–5.3). Most of
the patients (11 of 12) presented VL > 1000 copies/mL. Subop-
timal adherence was common (7 of 12). Information about the
correctness of the antiretroviral dosages prescribed was avail-
able for 10 of 12, and 7 of 10 had been exposed to subtherapeu-
tic doses for periods ranging from 2 months to 3 years. All
prescription errors were due to failure to adjust the doses to
the current weight, affecting in most cases all the regimen
drugs. Only 4 of 12 children met the WHO criteria for clinical
and/or immunological failure: patients #6 and #12 presented
both immunological and clinical failure with persistent CD4
levels below 100 cell/mm3 and severe malnutrition; patient #4
had persistent CD4 levels below 100 cell/mm3; and patient
#10 presented clinical failure due to severe malnutrition, and al-
though the CD4 evolution was unsatisfactory he did not met the
WHO criteria for immunological failure.
Genotypic Resistance Proﬁle
Ten children carried virus with double resistance to NNRTIs
and nucleoside/nucleotide reverse-transcriptase inhibitors
(NRTIs). None harbored major resistance to protease inhibitors
(PIs) (Table 1).
Nucleotide reverse-transcriptase inhibitor mutations were
seen in 11 of 12 patients, mostly M184V (10 of 11). Six children
harbored thymidine analog mutations, the majority (5 of 6) car-
rying ≥2. Non-nucleoside reverse-transcriptase inhibitor muta-
tions were observed in 11 of 12 children, and K103N was the
most common (5 of 11).
Pre-ART plasma samples were available for 7 of 10 patients
enrolled at HIV diagnosis. None of them presented pre-ART
drug-resistance mutations, suggesting that they developed
these mutations after treatment initiation. For another patient
(#9), diagnosed together with her mother after cessation of
breastfeeding, a pre-ART sample from the mother did not
show resistance-associated mutations. The remaining 4 children
presented history of poor adherence and/or underdosage of
drugs, rendering the acquisition of resistance mutations likely.
Outcome
All patients were switched to a PI boosted with ritonavir
(PI/r) + 2 NRTIs regimen. Based on the resistance testing, the
regimens prescribed contained no predicted active NRTI in 5
of 12 cases, and 1 predicted active NRTI in 6 of 12 cases.
Only 1 patient obtained a regimen with 2 active NRTIs.
By the time of the analysis, 6 of 12 children were under active
follow-up and had completed 6 months of second-line ART
with good self-reported adherence and compatible pill count-
ing, 2 of 12 had not completed 6 months on the PI/r-based reg-
imen, 1 of 12 had interrupted ART repeatedly, 2 of 12 had been
transferred, and 1 had stopped ART (Table 1).
Viral load was performed in 4 of 6 children who had com-
pleted 6 months on second-line ART, and 3 of 4 presented sat-
isfactory VL reduction. The remaining patient, aged 17,
presented a VL 5-fold higher than the one when VF was detect-
ed, but HIV genotyping showed no drug-resistance mutations,
suggesting low compliance with ART.
DISCUSSION
This case series raises concern about a scarcely reported emerg-
ing public health concern in sub-Saharan Africa. To our knowl-
edge, only 1 study from Kenya has described the pattern of
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Table 1. Clinical Characteristics and Antiretroviral Drug-Resistance Mutations of 12 Children Living With HIV in Rural Tanzania
Child
Age at
ART
Initiation
(Years)
Orphan
Status
Baseline
HIV
Genotyping
CD4 Count in
Cell/mm3 (and
%) at ART
Initiation
1st-Line ART
Regimens
Prescribed
Number of
1st-Line
ART
Switches
History of
Suboptimal
Adherence
Under
Dosage
of Drugs
Time on
ART When
DRM
Detected
(Years)
VL at the Time
of Treatment
Failure
Detection
(Copies/mL)
NNRTI
Resistance
Mutations
NRTI
Resistance
Mutations
2nd-Line
Regimens
VL ≥ 6 Months
After Switched
to 2nd-Line
(Copies/mL)
1 4.5 Maternal
orphan
No DRM 238 (7%) d4T/3TC/NVP N/A Yes Yes 4.6 5396 A98G,
K103N,
V108I, K238T
M41L, V75M,
M184V,
L210W, T215Y
TDF/FTC/
LPV/r
Not donea
2 4.9 Double
orphan
No DRM 425 (13%) d4T/3TC/NVP
AZT/3TC/NVP
TDF/3TC/EFV
3 No Yes 3.4 330 Y181C M184V TDF/FTC/
LPV/r
Undetectable
3 13.2 Non-orphan No DRM 317 (10%) AZT/3TC/EFV
TDF/3TC/EFV
1 Yes No 2.7 22 071 V90IV,
K103N,
P225H
Y115FY,
M184MV
AZT/3TC/
ATV/r
N/Ab
4 6.1 Paternal
orphan
No DRM 152 (12%) d4T/3TC/NVP N/A No Yes 1.2 174 546 A98G,
K103N,
V108I, K
238T
M41L, V75M,
M184V,
L210W, T215Y
TDF/FTC/
LPV/r
345
5 11.7 Paternal
orphan
No DRM 124 (12%) d4T/3TC/NVP
AZT/3TC/NVP
1 Yes No 3.3 1340 K101E,
Y181C,
H221Y
– TDF/FTC/
ATV/r
TDF/FTC/
LPV/r
N/Ac
6 11.5 Paternal
orphan
No DRM 16 (1%) AZT/3TC/EFV
AZT/3TC/NVP
2 Yes Yes 4.0 22 623 K103KN M184IMV,
L210LW
TDF/FTC/
LPV/r
ABC/3TC/
LPV/r
124 276
7 8.7 Double
orphan
Not doned 375 (12%) AZT/3TC/EFV N/A No Yes 5.8 1478 – M184V TDF/FTC/
ATV/r
TDF/FTC/
LPV/r
N/Ae
8 6.6 Maternal
orphan
No DRM 331 (10%) AZT/3TC/EFV N/A Yes N/A 3.3 31 000 L100I, Y188L M184V TDF/FTC/
LPV/r
N/Ac,f
9 0.8 Non-orphan Not doned,g 66 (2%) d4T/3TC/NVP
AZT/3TC/NVP
2 No No 5.1 5648 K101E,
G190A
M41L, D67N,
T69L, V75M,
M184V,
L210W, T215Y
TDF/FTC/
LPV/r
Undetectable
10 5.4 Maternal
orphan
Not doned 201 (3%) d4T/3TC/NVP
AZT/3TC/EFV
1 Yes N/A 7.0 3775 V90I, K103N,
V108I, K238T
M41L, D67G,
K70R, V75M,
M184V,
L210W, T215F,
K219E
TDF/FTC/
LPV/r
N/Ah
11 5.8 Double
orphan
N/Ai 158 (no %
information)
AZT/3TC/EFV N/A Yes Yes 1.8 Not donea A98AG,
K101P,
K103N,
E138AE
M184V, T215F TDF/FTC/
LPV/r
Not donea
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acquired drug-resistance mutations in children failing ART in
Africa [8]. In this cohort study, 34% (34 of 100) of patients pre-
sented VF, of whom 68% (23 of 34) had drug-resistance muta-
tions, 14 of 23 harboring multiclass mutations. Similar to our
ﬁndings, the common mutations were M184V and K103N. Fac-
tors related to VF in children, such as suboptimal adherence,
nonparental caregiver, and ART regimen switches [1, 12, 13],
were common among our patients. Furthermore, we have iden-
tiﬁed a frequently overlooked factor: the prescription of inade-
quate doses of antiretrovirals. Awareness needs to be raised
among health workers, and tools to facilitate the prescription
of pediatric formulations need to be widely disseminated and
routinely used [14].
Importantly, 8 of 12 children did not meet the WHO criteria
of clinical or immunological failure [15] despite presenting with
multiclass drug-resistance mutations, thus emphasizing the ur-
gent need for routine VL monitoring in children.
Four patients had VLmonitored 6 months after switching. One
teenager had a very high VL but no evidence of drug-resistance
mutations, suggesting that both self-reported and pill-counting
adherence were inaccurate. This case is a reminder of the difﬁcul-
ties among some adolescents to adhere to ART. Strategies to im-
prove disclosure of infection status and adherence need to be
further developed in partnership with teenagers.
Most patients (11 of 12) could not receive 3 active second-line
drugs. Recent studies show that the rates of virologic suppression
after switching to a PI/r + 2NRTIs regimen remain high despite
resistance to both NRTI and NNRTI [8, 16]. However, these ﬁnd-
ings require further conﬁrmation in children, who present a high-
er rate of acquired drug-resistance mutations and face the
challenges of longer exposure to ART than adults. Yet, in most
African settings, few pediatric regimens are available, and advo-
cating for child-friendly formulations is necessary. The inclusion
of integrase inhibitors such as dolutegravir in pediatric ART pro-
grams in resource-limited settings needs to be explored urgently.
The upcoming clinical trial PENTA 20 (www.clinicaltrials.gov)
may provide key information to support its rollout in Africa.
This study has limitations. First, it presents a small number of
patients. However, given the scarcity of published data on ac-
quired drug-resistance mutations in children in Africa, it pro-
vides a valuable insight into this public health concern.
Second, we are unable to assess the prevalence of acquired
drug-resistance mutations. However, preliminary results of an
ongoing study in our cohort identiﬁed 25% prevalence of VF
among children on ART (L. M., personal communication). Fi-
nally, it is possible that the mutations in the pre-ART plasma
samples dropped below the level of detection of the genotypic
assay used and we were not able to detect them.
CONCLUSIONS
In conclusion, after a decade of successful rollout of ART in Af-
rica, children and adolescents still represent an underprivilegedTa
bl
e
1
co
nt
in
ue
d.
C
hi
ld
A
ge
at
A
R
T
In
iti
at
io
n
(Y
ea
rs
)
O
rp
ha
n
S
ta
tu
s
B
as
el
in
e
H
IV
G
en
ot
yp
in
g
C
D
4
C
ou
nt
in
C
el
l/m
m
3
(a
nd
%
)a
t
A
R
T
In
iti
at
io
n
1s
t-L
in
e
A
R
T
R
eg
im
en
s
P
re
sc
rib
ed
N
um
be
r
of
1s
t-L
in
e
A
R
T
S
w
itc
he
s
H
is
to
ry
of
S
ub
op
tim
al
A
dh
er
en
ce
U
nd
er
D
os
ag
e
of
D
ru
gs
Ti
m
e
on
A
R
T
W
he
n
D
R
M
D
et
ec
te
d
(Y
ea
rs
)
V
L
at
th
e
Ti
m
e
of
Tr
ea
tm
en
t
Fa
ilu
re
D
et
ec
tio
n
(C
op
ie
s/
m
L)
N
N
R
TI
R
es
is
ta
nc
e
M
ut
at
io
ns
N
R
TI
R
es
is
ta
nc
e
M
ut
at
io
ns
2n
d-
Li
ne
R
eg
im
en
s
V
L
≥
6
M
on
th
s
A
ft
er
S
w
itc
he
d
to
2n
d-
Li
ne
(C
op
ie
s/
m
L)
12
7.
0
D
ou
bl
e
or
ph
an
N
/A
i
N
o
in
fo
rm
at
io
n
A
ZT
/3
TC
/E
FV
A
B
C
/3
TC
/E
FV
1
N
o
Ye
s
7.
3
38
6
40
0
A
98
G
,
K
10
3S
,
G
19
0A
,
Y
31
8F
M
41
L,
D
67
N
,
L7
4I
,M
18
4V
,
L2
10
W
,T
21
5Y
TD
F/
FT
C
/
LP
V
/r
N
/A
e
A
bb
re
vi
at
io
ns
:A
B
C
,a
ba
ca
vi
r;
A
R
T,
an
tir
et
ro
vi
ra
lt
re
at
m
en
t;
A
TV
/r,
rit
on
av
ir-
bo
os
te
d
at
az
an
av
ir;
A
ZT
,z
id
ov
ud
in
e;
d4
T,
st
av
ud
in
e;
D
R
M
,d
ru
g-
re
si
st
an
ce
m
ut
at
io
n;
E
FV
,e
fa
vi
re
nz
;F
TC
,e
m
tr
ic
ita
bi
ne
;H
IV
,h
um
an
im
m
un
od
ef
ic
ie
nc
y
vi
ru
s;
LP
V
/r,
rit
on
av
ir-
bo
os
te
d
lo
pi
na
vi
r;
N
/A
,n
ot
ap
pl
ic
ab
le
;N
N
R
TI
,n
on
-n
uc
le
os
id
e
re
ve
rs
e-
tr
an
sc
rip
ta
se
in
hi
bi
to
r;
N
R
TI
,n
uc
le
os
id
e/
nu
cl
eo
tid
e
re
ve
rs
e-
tr
an
sc
rip
ta
se
in
hi
bi
to
r;
N
V
P,
ne
vi
ra
pi
ne
;T
D
F,
te
no
fo
vi
r
di
so
pr
ox
il
fu
m
ar
at
e;
V
L,
vi
ra
ll
oa
d;
3T
C
,l
am
iv
ud
in
e.
a
V
ira
ll
oa
d
no
t
do
ne
du
e
to
a
te
ch
ni
ca
lp
ro
bl
em
.
b
Th
e
pa
tie
nt
op
te
d
to
st
op
A
R
T.
c
A
t
th
e
tim
e
of
th
e
m
an
us
cr
ip
t
w
rit
in
g,
th
e
pa
tie
nt
ha
d
no
t
ye
t
co
m
pl
et
ed
6
m
on
th
s
on
se
co
nd
-li
ne
A
R
T.
d
P
re
-A
R
T
sa
m
pl
e
w
as
no
t
av
ai
la
bl
e.
e
Th
e
pa
tie
nt
w
as
tr
an
sf
er
re
d
to
an
ot
he
r
fa
ci
lit
y
be
fo
re
co
m
pl
et
in
g
6
m
on
th
s
on
se
co
nd
-li
ne
A
R
T.
f
V
ira
ll
oa
d
w
as
do
ne
6
w
ee
ks
af
te
r
ha
vi
ng
be
en
sw
itc
he
d
to
se
co
nd
-li
ne
an
d
w
as
26
0
co
pi
es
/m
L.
g
Th
e
m
ot
he
r’s
pr
e-
A
R
T
sa
m
pl
e
ge
no
ty
pe
di
d
no
t
sh
ow
D
R
M
s.
h
Th
e
pa
tie
nt
in
te
rr
up
te
d
A
R
T
3
tim
es
si
nc
e
sw
itc
he
d
to
se
co
nd
-li
ne
A
R
T.
i
Th
e
pa
tie
nt
in
iti
at
ed
A
R
T
in
an
ot
he
r
fa
ci
lit
y
an
d
pr
e-
A
R
T
sa
m
pl
e
w
as
no
t
av
ai
la
bl
e.
4 • OFID • BRIEF REPORT
population. Antiretroviral treatment coverage is lower and fail-
ure rates are higher than in adults. Children living with HIV
have peculiarities and needs that must be acknowledged by
the often overwhelmed health workers, and speciﬁc policies tar-
geting the pediatric population should be implemented. More-
over, VL is not available in most African treatment centers,
leading invariably to a late recognition of failure and develop-
ment of multiclass drug-resistance mutations. New classes of
antiretrovirals and their adequate pediatric formulation are ur-
gently needed to ensure the long-term survival of millions of
children living with HIV in sub-Saharan Africa.
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